Prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 diabetes: The Verona newly diagnosed type 2 diabetes study (VNDS)

Diabetes Care

Volumn 38, Issue 8, 2015, Pages 1487-1493

  Zoppini, Giacomo ^a   Cacciatori, Vittorio ^a   Raimondo, Daniele ^a   Gemma, Marialuisa ^a   Trombetta, Maddalena ^a   Dauriz, Marco ^a   Brangani, Corinna ^a   Pichiri, Isabella ^a   Negri, Carlo ^a   Stoico, Vincenzo ^a   Bergamini, Corinna ^a   Targher, Giovanni ^a   Santi, Lorenza ^a   Thomaseth, Karl ^b   Bellavere, Federico ^b   Bonadonna, Riccardo C ^a   Bonora, Enzo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PREVALENCE; PULSE PRESSURE; SEX DIFFERENCE; SMOKING HABIT; TRIGLYCERIDE CHOLESTEROL RATIO; AGED; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; EARLY DIAGNOSIS; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; NEUROLOGIC EXAMINATION; PHYSIOLOGY;

AGED; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; EARLY DIAGNOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; TRIGLYCERIDES;

EID: 84962408684     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0081     Document Type: Article

References (40)

1. Kahn R. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Clinical measures. Diabetes Care 1992;15:1081-1083.
2. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig 2013; 4:4-18.
3. Singh JP, Larson MG, O'Donnell CJ, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000;86:309-312.
4. Young LH, Wackers FJ, Chyun DA, et al.; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled study. JAMA 2009; 301:1547-1555.
5. Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab 1986;15:855-888.
6. Ewing DJ, Marryn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8:491-498.
7. Spallone V, Ziegler D, Freeman R, et al.; Toronto Consensus Panel on Diabetic Neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011;27: 639-653.
8. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F; The Diacan Multicenter Study Group. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. Diabetes Metab 1993;19: 143-151.
9. Valensi P, Paries J, Attali JR; French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complicationsdthe French multicenter study. Metabolism 2003; 52:815-820.
10. Spallone V, Bellavere F, Scionti L, et al.; Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 2011;21:69-78.
11. McDaid EA, Monaghan B, Parker AI, Hayes JR, Allen JA. Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. Diabetes Care 1994;17:1422-1427.
12. Ratzmann KP, Raschke M, Gander I, Schimke E. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. J Diabet Complications 1991;5:1-5.
13. Lehtinen JM, Uusitupa M, Siitonen O, Pyörala K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989;38:1307-1313.
14. Jyotsna VP, Sahoo A, Sreenivas V, Deepak KK. Prevalence and pattern of cardiac autonomic dysfunction in newly detected type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 83:83-88.
15. Rota E, Quadri R, Fanti E, et al. Clinical and electrophysiological correlations in type 2 diabetes mellitus at diagnosis. Diabetes Res Clin Pract 2007;76:152-154.
16. Charles M, Ejskjaer N, Witte DR, Borch- Johnsen K, Lauritzen T, Sandbaek A. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: The ADDITIONDenmark study. Diabetes Care 2011;34:2244- 2249.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470.
18. Zoppini G, Cacciatori V, Gemma ML, et al. Effect of moderate aerobic exercise on sympatho- vagal balance in Type 2 diabetic patients. Diabet Med 2007;24:370-376.
19. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1998;46:1470.
20. Assessment: clinical autonomic testing report of the Therapeutic and Technology Assessment Subcommittee of the America Academy of Neurology. Neurology 1996;46:873-880.
21. American Diabetes Association American Academy of Neurology. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11:592-597.
22. Smith SA. Reduced sinus arrhythmia in diabetic autonomic neuropathy: diagnostic value of an age-related normal range. Br Med J (Clin Res Ed) 1982;285:1599-1601.
23. Balzani I, De Masi G, Carraro M, Carenza P, Thomaseth K, Bellavere F. Valori di normalita dei test cardiovascolari per la diagnosi di neuropatia autonomica diabetica ottenuti con acquisizione computerizzata ed analisi automatica della variazioni di frequenza cardiaca. Atti del XIII Congresso Nazionale SID. Diabete 1991;3 (Suppl. 2):787-789.
24. Chang CJ, Yang YC, Lu FH, et al. Altered cardiac autonomic function may precede insulin resistance in metabolic syndrome. Am J Med 2010;123:432-438.
25. Wu JS, Yang YC, Lin TS, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab 2007;92:3885-3889.
26. Bergström B, Lilja B, Osterlin S, Sundkvist G. Autonomic neuropathy in non-insulin dependent (type II) diabetes mellitus. Possible influence of obesity. J Intern Med 1990;227:57-63.
27. Masuo K, Mikami H, Itoh M, Ogihara T, Tuck ML. Sympathetic activity and body mass index contribute to blood pressure levels. Hypertens Res 2000;23:303-310.
28. Tracey KJ. The inflammatory reflex. Nature 2002;420:853-859.
29. Belin de Chantemele EJ, Stepp DW. Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol 2012;52:840-847.
30. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 2011;58: 271-279.
31. Lambert E, Lambert G, Ika-Sari C, et al. Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. Hypertension 2011;58:43-50.
32. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998;31: 68-72.
33. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications 2011;25:159-167.
34. Ayad F, Belhadj M, Paries J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med 2010;27:804-811.
35. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Glucose tolerance and other determinants of cardiovascular autonomic function: The Hoorn Study. Diabetologia 2000;43:561-570.
36. Spallone V, Maiello MR, Cicconetti E, Menzinger G. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes Res Clin Pract 1997;34:169-179.
37. Vinik AI, Murray GL. Autonomic neuropathy is treatable. US Endocrinol 2008;4:82-84.
38. American Diabetes Association. Standards of medical care in diabetesd2015: summary of revisions. Diabetes Care 2015;38 (Suppl. 1):S4.
39. Charles M, Fleischer J, Witte DR, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screendetected diabetes: ADDITION-Denmark, a clusterrandomised study. Diabetologia 2013;56: 101-108.
40. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348: 383-393.